BusinessDr Lal PathLabs Acquires 70% Stake in SN Genelab for ₹168 Crore
Dr Lal PathLabs is acquiring a 70% stake in SN Genelab for ₹168 crore, with an additional ₹31.5 crore payable if performance targets are met. SN Genelab's FY26 revenue was ₹58 crore, about 2% of Dr Lal's last year revenue. The acquisition may slightly dilute earnings per share initially but could boost growth by expanding genomics testing through Dr Lal's extensive network, especially in western India.
Mint Markets·4h ago




